Results 11 to 20 of about 1,815 (184)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus [PDF]

Journal of Diabetes Research, 2018
Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin ...
Shinji Kamei, Masahiro Iwamoto, Miyuki Kameyama, Masashi Shimoda, Tomoe Kinoshita, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Fuminori Tatsumi, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +13 more
doaj   +3 more sources

Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice [PDF]

BMC Gastroenterology
Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes ...
Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata   +11 more
doaj   +2 more sources

Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy. [PDF]

J Endocr Soc
Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors are effective medications for type 2 diabetes (T2D), chronic kidney disease and chronic heart failure regardless of diabetic status. However, concerns remain about their potential to reduce skeletal muscle mass.
Kishida C, Murakoshi M, Sakuma H, Shibata T, Suzuki Y, Gohda T.   +5 more
europepmc   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice [PDF]

Journal of Diabetes Investigation
Aims/Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety.
Yuichiro Yamada, Daisuke Yabe, Kenichiro Shide, Atsushi Suzuki, Yasuo Terauchi, Yasunori Sato, Nobuyuki Shihara, Yutaka Seino   +7 more
doaj   +2 more sources

A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database [PDF]

Scientific Reports
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of drugs used in the clinical management of patients with type 2 diabetes, and their prescriptions have been increasing in recent years.
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji, Kohei Shiota, Nanaka Ichihara, Moe Yamashita, Yuka Nokura, Tomofumi Yamazaki, Kana Sugishita, Hideyuki Tanaka, Hirofumi Tamaki, Motoyuki Ishiguro, Kazuhiro Iguchi, Mitsuhiro Nakamura   +16 more
doaj   +2 more sources

Comparative Efficacy of SGLT2 Inhibitors in MASLD: Bayesian Network Meta-Analysis of CAP-LSM Outcomes and Time Effects. [PDF]

JGH Open
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide. Sodium–glucose cotransporter‐2 (SGLT2) inhibitors, glucose‐lowering agents with cardiovascular benefits, have shown hepatoprotective potential.
Gomez DP, Hababag WF, Ong-Ramos CC.
europepmc   +2 more sources

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion [PDF]

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +2 more sources

A decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes. [PDF]

J Diabetes Investig
Journal of Diabetes Investigation, Volume 16, Issue 12, Page 2142-2144, December 2025.
Kimura T, Kaku K.
europepmc   +2 more sources

Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review. [PDF]

Endocrinol Diabetes Metab
The study suggests that prolonged use of Pioglitazone, Repaglinide and Alogliptin may significantly slow CIMT progression, improving cardiovascular risk management in patients with diabetes and/or cardiovascular disease. Further research is needed to understand the benefits and optimise oral hypoglycaemic treatment strategies for these patients ...
Shabu A, Naqvi SM, Hesari F, Naqvi SY, Tawfick W.   +4 more
europepmc   +2 more sources

Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats

BMJ Open Diabetes Research & Care, 2021
Introduction Sodium glucose cotransporter-2 (SGLT2) inhibitors are widely used for diabetes treatment. Although SGLT2 inhibitors have been clinically observed to increase food intake, roles or even the presence of SGLT2 in the central nervous system (CNS)
Kenji Takeda, Hiraku Ono, Ko Ishikawa, Tomohiro Ohno, Jin Kumagai, Hidetoshi Ochiai, Ai Matumoto, Hidetaka Yokoh, Koutaro Yokote   +8 more
doaj   +1 more source